Safinamide: First global approval

Drugs

Volumn 75, Issue 6, 2015, Pages 705-711

  Deeks, Emma D ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTIPARKINSON AGENT; BENZYLAMINE DERIVATIVE; SAFINAMIDE;

ANALOGS AND DERIVATIVES; ANIMAL; COGNITION DISORDERS; DRUG APPROVAL; DYSKINESIA, DRUG-INDUCED; HUMAN; INTERNATIONAL COOPERATION; PARKINSON DISEASE;

ALANINE; ANIMALS; ANTIPARKINSON AGENTS; BENZYLAMINES; COGNITION DISORDERS; DRUG APPROVAL; DYSKINESIA, DRUG-INDUCED; HUMANS; INTERNATIONALITY; PARKINSON DISEASE;

EID: 84937761150     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0389-7     Document Type: Article

References (34)

1. Schapira AHV. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs. 2011;25:1061-71.
2. Grosset DG, Macphee GJ, Nairn M. Diagnosis and pharmacological management of Parkinson's disease: summary of SIGN guidelines. BMJ. 2010;340:b5614.
3. Parkinson's Disease Foundation. Treating Parkinson's: understanding medications. 2014. http://www.pdf.org. Accessed 13 Mar 2015.
4. AgingCare. What is "time off" and "wearing off" in Parkinson's disease? 2015. http://www.agingcare.com. Accessed 13 Mar 2015.
5. Fox SH. Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs. 2013;73(13):1405-15.
6. Kulisevsky J. Emerging role of safinamide in Parkinson's disease therapy. Eur Neurol Rev. 2014;9(2):108-12.
7. Zambon S.p.A. Xadago film-coated tablets: summary of product characteristics. 2015. http://ec.europa.eu/. Accessed 10 Mar 2015.
8. ® (safinamide) for mid-late stage PD patients [media release]. 2015. http://www.zambongroup.com.
9. Newron Pharmaceuticals. Safinamide new drug application (NDA) submitted to the US Food and Drug Administration (FDA). Media release. 2014. http://www.newron.com.
10. Newron Pharmaceuticals and Zambon S.p.A. Refusal to file letter received from US FDA for safinamide, based on organization and navigation problems. Media release. 2014. http://www.newron.com.
11. ® (safinamide) new drug application (NDA) accepted for filing by the U.S. Food and Drug Administration (FDA) [media release]. 2015. http://www.newron.com.
12. Newron Pharmaceuticals. Safinamide new drug application (NDA) re-submitted to the US Food and Drug Administration (FDA) [media release]. 2014. http://www.newron.com.
13. Newron Pharmaceuticals S.p.A. Newron and Zambon enter into a strategic collaboration and licence agreement for Safinamide [media release]. 2012. http://www.newron.com.
14. Newron Pharmaceuticals S.p.A. Newron and Zambon enter into strategic collaboration and licence option for Safinamide in the EU and US [media release]. 2012. http://www.newron.com.
15. Newron Pharmaceuticals S.p.A. Newron signs license agreement with Meiji Seika Pharma for safinamide covering Japan and key Asian territories [media release]. 2012. http://www.newron.com.
16. Serono and Newron Pharmaceuticals S.p.A. Serono and Newron announce global development and commercialization agreement for safinamide [media release]. 2006. http://www.serono.com.
17. Newron Pharmaceuticals S.p.A. Newron regains full global rights to safinamide from Merck Serono [media release]. 2011. http://www.newron.com.
18. Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67(7 Suppl 2):S18-23.
19. Podurgiel SA, Collins-Praino LEA, Yohn SA, et al. Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. Pharmacol Biochem Behav. 2013;105(Supplement(C)):105-11.
20. Gregoire L, Jourdain VA, Townsend M, et al. Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord. 2013;19(5):508-14.
21. Marquet A, Kupas K, Johne A, et al. The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Clin Pharmacol Ther. 2012;92(4):450-7.
22. Cattaneo C, Caccia C, Marzo A, et al. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin Neuropharmacol. 2003;26(4):213-7.
23. Di Stefano AF, Rusca A. Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2011;384(6):505-15.
24. Marzo A, Dal Bo L, Monti NC, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004;50(1):77-85.
25. Leuratti C, Sardina M, Ventura P, et al. Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers. Pharmacology. 2013;92(3-4):207-16.
26. Krosser S, Marquet A, Gallemann D, et al. Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects. Biopharm Drug Dispos. 2012;33(9):550-9.
27. Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord. 2014;29(2):229-37.
28. Anand R, Lucini V, Forrest E, et al. Early onset of efficacy of safinamide on motor fluctuations in PD patients on l-dopa and other PD medications (SETTLE study) [abstract]. Mov Disord. 2014;29(Suppl 1):608.
29. Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Mov Disord. 2014;29(10):1273-80.
30. Stocchi F, Borgohain R, Onofrj M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord. 2012;27(1):106-12.
31. Newron Pharmaceuticals S.p.A. and Zambon S.p.A. Safinamide phase III MOTION and SETTLE study results presented at 2013 American Academy of Neurology (AAN) Annual Meeting [media release]. 2013. http://www.newron.com.
32. Barone P, Fernandez H, Ferreira J, et al. Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION Study) [abstract no. P01.061]. Neurology. 2013;80(Meeting Abstracts 1).
33. Schapira AH, Stocchi F, Borgohain R, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Eur J Neurol. 2013;20(2):271-80.
34. Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63(4):746-8.